Phaseline

Companies › Hangzhou Huasai Biomedicine

Hangzhou Huasai Biomedicine: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HS-IT101 Injection
Autologous tumor-infiltrating lymphocyte (TIL) therapy
–Phase 2Melanoma (Excluding Uveal Melanoma); Advanced Non-Small Cell Lung Cancer; Solid Tumor; Clear Cell Renal Cell Carcinoma …Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07105176HS-IT101 InjectionPhase 1Advanced Non-Small Cell Lung CancerOncologyAug 2027
NCT07406724HS-IT101 InjectionPhase 2Melanoma (Excluding Uveal Melanoma)OncologyDec 2027
NCT06342336HS-IT101 InjectionPhase 1Solid TumorOncologyMar 2028
NCT07770802HS-IT101 InjectionPhase 1Clear Cell Renal Cell CarcinomaOncologyAug 2028
NCT07830342HS-IT101 InjectionPhase 1Advanced NSCLCOncologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.